Administration of CXCR7-agonist TC14102 retards these pro-fibrotic changes, demonstrating its therapeutic potential to ameliorate hepatic fibrosis and to promote regenerative mechanisms [105]. This evidence concerns the gene ACKR3 and Hepatic fibrosis.